Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5560379 | 0.83 | POLB (0.65) | BRD4CA12CA9MAPTHDAC3 | |
| SCHEMBL5559592 | 0.83 | MAPT (0.53) | BRD4CA12CA9MAPTHDAC3 | |
| SCHEMBL1318958 | 0.82 | KDM4E (0.64) | BRD4KDM4ESLC22A12ALDH1A1 | |
| SCHEMBL4771765 | 0.81 | HDAC3 (0.53) | BRD4CA12CA9MAPTHDAC3 | |
| SCHEMBL5317017 | 0.81 | HDAC3 (0.56) | BRD4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1093189 | 0.79 | POLB (0.67) | BRD4SLC22A12GAAALDH1A1 | |
| SCHEMBL5315898 | 0.78 | KDM4E (0.64) | KDM4EGAAL3MBTL1ALDH1A1KMT2A | |
| SCHEMBL14057926 | 0.78 | MAPT (0.74) | CA12CA9MAPTHDAC3HDAC4 | |
| SCHEMBL5560159 | 0.77 | KDM4E (0.71) | BRD4CA12CA9KDM4EALDH1A1 | |
| SCHEMBL24845442 | 0.75 | LMNA (0.55) | BRD4KDM4EHPGDSLC22A12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093453-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | ATHEROGENICS, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| US-7173129-B2 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | ATHERO GENICS, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20050049236-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | CRABTREE ACQUISITION CO, LLC | 2005-03-03 | — | — | US | disclosed |
| WO-2004108094-A2 | SULFONAMIDE-SUBSTITUTED CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | ATHEROGENICS, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049236-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | STS, HPSE, SULT1E1 | BRD4 998/4885CA12 1535/4885CA9 1619/4885 |
| US-20070093453-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | STS, HPSE, SULT1E1 | BRD4 998/4885CA12 1535/4885CA9 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.